A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL DOSE-ESCALATION RESULTS

被引：1

作者：

Johnson, Melissa ^{[1
]}

Lakhani, Nehal ^{[2
]}

Girda, Eugenia ^{[3
]}

Olszanski, Anthony ^{[4
]}

Fong, Lawrence ^{[5
]}

Han, Hyunsil ^{[6
]}

Casey, Kerry ^{[6
]}

Li, Siyu ^{[6
]}

Visich, Jennifer ^{[6
]}

Skokos, Dmitris ^{[6
]}

Seebach, Frank ^{[6
]}

Lowy, Israel ^{[6
]}

Fury, Matthew ^{[6
]}

Mathias, Melissa ^{[6
]}

Segal, Neil ^{[7
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] START Midwest, Grand Rapids, MI USA

[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[4] Fox Chase Canc Ctr, Philadelphia, PA USA

[5] Univ Calif San Francisco, San Francisco, CA USA

[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[7] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0735

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

735

引用

页码：A767 / A768

页数：2

共 50 条

[1] A PHASE I/II STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS
Lakhani, Nehal
Johnson, Melissa
Groisberg, Roman
Han, Hyunsil
Casey, Kerry
Li, Siyu
Skokos, Dimitris
Seebach, Frank
Lowy, Israel
Fury, Matthew
Mathias, Melissa
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A565 - A565
[2] A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Trial-inprogress update.
Segal, Neil Howard
Pelster, Meredith
Girda, Eugenia
Fong, Lawrence
Olszanski, Anthony J.
Han, Hyunsil
Casey, Kerry A.
Li, Siyu
Welf, Erik
Chen, Chieh-I
Skokos, Dimitris
Seebach, Frank A.
Lowy, Israel
Fury, Matthew G.
Mathias, Melissa Divya
Lakhani, Nehal J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS277 - TPS277
[3] A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update
Segal, Neil Howard
Girda, Eugenia
Sohal, Davendra
Lakhani, Nehal J.
Olszanski, Anthony J.
Fong, Lawrence
Han, Hyunsil
Casey, Kerry A.
Li, Siyu
Ganguly, Samit
Seebach, Frank A.
Mathias, Melissa Divya
Pelster, Meredith
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS239 - TPS239
[4] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
Segal, Neil Howard
Girda, Eugenia
Sohal, Davendra
Lakhani, Nehal J.
Olszanski, Anthony J.
Fong, Lawrence
Kinnaman, Michael David
Han, Hyunsil
Skokos, Dimitris
Casey, Kerry A.
Wang, JuAn
Wang, Bei
Hao, Yi
Li, Siyu
Ganguly, Samit
Lowy, Israel
Seebach, Frank A.
Mathias, Melissa Divya
Johnson, Melissa Lynne
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] A Phase 1/2 Study of REGN7075 (EGFRA-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update
Johnson, M. L.
Girda, E.
Sohal, D.
Lakhani, N. J.
Olszanski, A. J.
Fong, L.
Kinnaman, M.
Han, H.
Moesta, A.
Hao, Y.
Li, S.
Ganguly, S.
Seebach, F.
Mathias, M.
Segal, N. H.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S391 - S391
[6] A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results
Lakhani, Nehal J.
Hamid, Omid
Brana, Irene
Lostes-Bardaji, M. Julia
Gajate, Pablo
Lopez-Criado, Maria Pilar
Swiecicki, Paul
de Miguel, Maria J.
Gil-Martin, Marta
Moreno, Victor
Muller, Aixa Elena Soyano
Ortiz, Ana Gonzalez
Sun, Dylan
Modi, Dimple
Zheng, Wenjun
Jankovic, Vladimir
Salvati, Mark
Fury, Matthew G.
Cristea, Mihaela C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
Shimizu, Toshio
Powderly, John
Abdul Razak, Albiruni
Lorusso, Patricia
Miller, Kathy D.
Kao, Steven
Kongpachith, Sarah
Tribouley, Catherine
Graham, Michelle
Stoll, Brian
Patel, Maulik
Sahtout, Mohammad
Blaney, Martha
Leibman, Rachel
Golan, Talia
Tolcher, Anthony
FRONTIERS IN ONCOLOGY, 2024, 14
[8] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
Patnaik, Amita
Weiss, Glen J.
Rasco, Drew W.
Blaydorn, Lisa
Mirabella, Amy
Beeram, Murali
Guo, Wei
Lu, Sharon
Danaee, Hadi
McEachern, Kristen
Im, Ellie
Sachdev, Jasgit C.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
[9] Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
O'Cearbhaill, R. E.
Moore, K. N.
Yeku, O.
Liu, J. F.
Bouberhan, S.
Hamilton, E. P.
Hou, J. Y.
Van Nieuwenhuysen, E.
Papadimitriou, K.
Yoo, S-Y.
Govindraj, S.
Brouwer-Visser, J.
Peterman, M.
Schmidt, T.
Barnes, B.
Madia, P.
Zhu, M.
Uldrick, T. S.
Miller, E. A.
O'Malley, D.
ANNALS OF ONCOLOGY, 2023, 34 : S516 - S517
[10] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
Zhang, Jingsong
Stein, Mark N.
Kelly, William Kevin
Tsao, Che-Kai
Falchook, Gerald Steven
Xu, Yuanfang
Seebach, Frank A.
Lowy, Israel
Mohan, Kosalai Kal
Kroog, Glenn
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

← 1 2 3 4 5 →